What is the Fmoc-L-citrulline?

Fmoc-L-citrulline is White to off white powder, while it's Molecular Formula is C 21 H 23 N 3 O 5 . White to off white powder

What is the CAS number for Fmoc-L-citrulline?

The CAS number of Fmoc-L-citrulline is 133174-15-9.

Product classification

Contact us

Tel：028 8868 0086

Phone：+86 18980008884

Website：https://www.zypeptides.com

Email：xuehaiying@zybiochem.com

Address： 170 Qingpu Road, Shou'an Town, Pujiang County, Chengdu City, Sichuan Province Chengdu ZY Biochemical Technology Co., Ltd.

133174-15-9

Product Name：Fmoc-L-citrulline
Molecular Formula：C21H23 N3 O5
Purity：99%
Molecular Weight：397.431

Inquiry Add to cart

Product Details;

CAS#： 133174-15-9

Molecular Formula： C21H23 N3 O5

Appearance： White to off white powder

Reputable Manufacturer Supply 133174-15-9 with Cheapest Price, Factory Sells Fmoc-L-Cit-OH

Molecular Formula:C₂₁H₂₃N₃O₅
Molecular Weight:397.431
Appearance/Colour:White to off white powder
Vapor Pressure:6.01E-19mmHg at 25°C
Melting Point:168-175ºC
Refractive Index:-10 ° (C=1, DMF)
Boiling Point:671.5oC at 760 mmHg
PKA:3.84±0.21(Predicted)
Flash Point:359.9oC
PSA：130.75000
Density:1.316g/cm3
LogP:3.90890

Fmoc-L-citrulline(Cas 133174-15-9) Usage

InChI:InChI=1/C21H23N3O5/c22-20(27)23-11-5-10-18(19(25)26)24-21(28)29-12-17-15-8-3-1-6-13(15)14-7-2-4-9-16(14)17/h1-4,6-9,17-18H,5,10-12H2,(H,24,28)(H,25,26)(H3,22,23,27)/t18-/m0/s1

133174-15-9 Relevant articles

A Wireframe DNA Cube: Antibody Conjugate for Targeted Delivery of Multiple Copies of Monomethyl Auristatin E

M?rcher, Anders,Nijenhuis, Minke A. D.,Gothelf, Kurt V.

supporting information, p. 21691 - 21696 (2021/09/02)

In recent years, several antibody drug c...

Improved Methodology for the Synthesis of a Cathepsin B Cleavable Dipeptide Linker, Widely Used in Antibody-Drug Conjugate Research

Mondal, Deboprosad,Ford, Jacob,Pinney, Kevin G.

supporting information, p. 3594 - 3599 (2018/09/11)

Antibody-drug conjugates (ADCs) represen...

DRUG-LINKER CONJUGATE PHARMACEUTICAL COMPOSITIONS

-

Paragraph 000158, (2017/05/02)

Compositions are disclosed having a cyto...

SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE

-

Page/Page column 81; 82, (2018/01/15)

The invention relates generally to a sil...

133174-15-9 Process route

: 372-75-8
Citrulline

: 28920-43-6
(fluorenylmethoxy)carbonyl chloride

: 133174-15-9
(S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-5-ureidopentanoic acid

Conditions

Conditions	Yield
Citrulline; With sodium hydrogencarbonate; In water; at 20 ℃; for 1h; (fluorenylmethoxy)carbonyl chloride; In 1,2-dimethoxyethane; water;	100%
With sodium hydrogencarbonate; In 1,2-dimethoxyethane; water; at 20 ℃; for 24h; Inert atmosphere;	96%
With potassium carbonate; In 1,4-dioxane; water; at 0 - 20 ℃; for 2h;	95.6%
With potassium carbonate; In 1,4-dioxane; water; at 0 - 20 ℃; for 2h;	95.6%
With potassium carbonate; In 1,4-dioxane; water; at 0 - 20 ℃; for 2h;	95.6%
With potassium carbonate; In 1,4-dioxane; water; at 0 - 20 ℃; for 2h;	95.6%
With potassium carbonate; In 1,4-dioxane; water; at 0 - 20 ℃; for 2h;	95.6%
With potassium carbonate; In 1,4-dioxane; water; at 0 - 20 ℃; for 2h;	95.6%
With potassium carbonate; In 1,4-dioxane; water; at 0 - 20 ℃; for 2h;	95.6%
With potassium carbonate; In 1,4-dioxane; water; for 2h; Inert atmosphere;	95%
With sodium carbonate; In 1,4-dioxane; water; at 0 - 20 ℃; for 2.08333h;

: 29022-11-5
N-(fluoren-9-ylmethoxycarbonyl)glycine

: 71989-31-6
Fmoc-Pro-OH

: 71989-14-5
Fmoc-(tBu)Asp-OH

: C₄₃H₄₃N₂O₆Pol

: 103213-32-7,167015-11-4
N-(9-fluorenylmethoxycarbonyl)-S-trityl-L-cysteine

: 71989-35-0,138797-71-4
Fmoc-Thr(tBu)-OH

: 132327-80-1,200623-62-7
Fmoc-L-Gln(Trt)-OH

: 134486-00-3,244028-70-4
(S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-(4-hydroxy-3-iodophenyl)propionic acid

: 133174-15-9
(S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-5-ureidopentanoic acid

: 204777-78-6
Fmoc-Lys(ivDde)-OH

: 187618-60-6
Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine

: Fmoc-Glu(ODmab)-OH

: C₁₇₉H₂₀₇IN₂₁O₂₉PolS₃

Conditions

Conditions	Yield
C₄₃H₄₃N₂O₆Pol; With piperidine; In N,N-dimethyl-formamide; for 0.5h; Rink amide MBHA resin Fmoc-Lys(ivDde)-OH; With 1-hydroxy-7-aza-benzotriazole; N-ethyl-N,N-diisopropylamine; HATU; In N,N-dimethyl-formamide; for 2.5h; Rink amide MBHA resin N-(fluoren-9-ylmethoxycarbonyl)glycine; Fmoc-Pro-OH; Fmoc-(tBu)Asp-OH; N-(9-fluorenylmethoxycarbonyl)-S-trityl-L-cysteine; Fmoc-Thr(tBu)-OH; Fmoc-L-Gln(Trt)-OH; (S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-(4-hydroxy-3-iodophenyl)propionic acid; (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-5-ureidopentanoic acid; Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine; Fmoc-Glu(ODmab)-OH; Further stages;

Yield

C₄₃H₄₃N₂O₆Pol; With piperidine; In N,N-dimethyl-formamide; for 0.5h; Rink amide MBHA resin

Fmoc-Lys(ivDde)-OH; With 1-hydroxy-7-aza-benzotriazole; N-ethyl-N,N-diisopropylamine; HATU; In N,N-dimethyl-formamide; for 2.5h; Rink amide MBHA resin

N-(fluoren-9-ylmethoxycarbonyl)glycine; Fmoc-Pro-OH; Fmoc-(tBu)Asp-OH; N-(9-fluorenylmethoxycarbonyl)-S-trityl-L-cysteine; Fmoc-Thr(tBu)-OH; Fmoc-L-Gln(Trt)-OH; (S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-(4-hydroxy-3-iodophenyl)propionic acid; (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-5-ureidopentanoic acid; Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine; Fmoc-Glu(ODmab)-OH; Further stages;

133174-15-9 Upstream products

372-75-8
Citrulline
28920-43-6
(fluorenylmethoxy)carbonyl chloride

133174-15-9 Downstream products

776305-25-0
2-(2-{3-[1-(4-bromo-phenyl)-ethyl]-ureido}-5-ureido-pentanoylamino)-3-methyl-butyric acid
1007391-44-7
symplocamide A
1449785-43-6
C₃₉H₃₄N₆O₉
1608127-09-8
C₂₂H₃₃N₅O₆

Relevant Products

Fmoc-L-Ala-OH·H2O
CAS：207291-76-7
FMOC-ALA-ALA-OH
CAS：87512-31-0
Boc-L-aspartic acid 4-tert-butyl ester
CAS：1676-90-0

Biochemical Engineering